Hydrosome Labs, a US biotechnology company focused on ultrafine bubble (UFB) technology, on Tuesday reported new findings from a study with Biocell Energetics, a venture from the University of Birmingham in the UK.
According to Hydrosome, the research demonstrated that winemaking/brewing yeast (Saccharomyces bayanus) grown in media infused with UFB water exhibited faster glucose metabolism and as much as a 31% increase in oxygen uptake rates compared to conventional fermentation using deionised water. These results suggest that Hydrosome Technology can significantly increase production output without requiring costly infrastructure changes.
The study involved real-time oxygen consumption monitoring and glucose utilisation tracking of UFBs on yeast respiration and metabolic performance. Findings include: a 31% increase in peak oxygen uptake at high UFB concentrations and 22% at medium levels versus a control without UFBs; up to 6X faster initial glucose consumption compared to the control; and a clear dose-response effect between UFB concentration and respiratory performance.
These results build on a 400-litre pilot study by Hydrosome Labs and the University of Illinois on E. coli fermentation, in which continuous UFB infusion doubled cell output, accelerated doubling time, and improved glucose utilisation by nearly threefold. That study also recorded a 14% increase in oxygen uptake, further validating UFBs as a tool for improving fermentation efficiency.
Hydrosome Labs says that it is partnering with companies across industries, including precision fermentation, functional beverages, and personal care, to scale these benefits through clean-label, chemical-free delivery systems.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Formation Bio acquires worldwide rights to FHND5032 from CTFH
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
Almirall receives China approval for Seysara to treat moderate-to-severe acne